School of Engineering
Showing 161-180 of 269 Results
-
Stephen Rock
Professor of Aeronautics and Astronautics, Emeritus
BioProfessor Rock's research interests include the application of advanced control and modeling techniques for robotic and vehicle systems (aerospace and underwater). He directs the Aerospace Robotics Laboratory in which students are involved in experimental programs designed to extend the state-of-the-art in robotic control. Areas of emphasis include planning and navigation techniques (GPS and vision-based) for autonomous vehicles; aerodynamic modeling and control for aggressive flight systems; underwater remotely-operated vehicle control; precision end-point control of manipulators in the presence of flexibility and uncertainty; and cooperative control of multiple manipulators and multiple robots. Professor Rock teaches several courses in dynamics and control.
-
Oscar Rodriguez
Graduate, Stanford Center for Professional Development
BioPursuing a Graduate Certificate in Artificial Intelligence. Outside of Stanford, I work on Machine Learning infrastructure for Gemini training setups at Google.
-
Carlos Jose Rodriguez Santiago
Ph.D. Student in Chemical Engineering, admitted Autumn 2022
BioCarlos Rodriguez Santiago is a Chemical Engineering PhD candidate working in the lab of Dr. Judith Shizuru to develop protein therapeutics that will facilitate hematopoietic stem cell transplantation without the need for chemotherapy or radiation. His PhD thesis work is at the intersection of immunology, oncology, and protein engineering. Carlos is also a Sarafan CheM-H Lipshultz Graduate Fellow participating in the Chemistry/Biology Interface (CBI) Predoctoral training program which aims to cultivate interactions and thinking across disciplinary lines to enable innovations that improve human health.
Prior to his PhD work, Carlos helped found the Protein Engineering Knowledge Center (PEKC) at Stanfords Innovative Medicines Accelerator (IMA). There he collaborated with researchers to discover and engineer antibodies against therapeutically relevant targets. Several antibodies discovered by Carlos have officially been licensed out for further therapeutic development.
